Form 8-K - Current report:
SEC Accession No. 0001493152-26-001170
Filing Date
2026-01-12
Accepted
2026-01-09 19:50:24
Documents
12
Period of Report
2026-01-08
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 36723
  Complete submission text file 0001493152-26-001170.txt   206130

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE telo-20260108.xsd EX-101.SCH 3087
3 XBRL LABEL FILE telo-20260108_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE telo-20260108_pre.xml EX-101.PRE 22368
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3433
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41952 | Film No.: 26524405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)